Lichen planus associated with hepatitis C virus: No viral transcripts are found in the lichen planus, and effective therapy for hepatitis C virus does not clear lichen planus

Journal of the American Academy of Dermatology

Volumn 49, Issue 5, 2003, Pages 847-852

  Harden, David ^a   Skelton, Henry ^b   Smith, Kathleen J ^b,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c Division of Human Gene Therapy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG EFFICACY; EOSINOPHIL; FEMALE; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LICHEN PLANUS; LYMPHOCYTIC INFILTRATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 0142182711     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(03)02089-9     Document Type: Article

References (36)

1. Pileri P, Uermatsu Y, Campagnodi S, Galli G, Falugi F, Falugi F, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-40.
2. Ginick G. Hepatitis C: controversies, strategies and challenges. Eur J Surg 1998;SS82(Suppl):65-70.
3. Zein NN. Interferons in the management of viral hepatitis. Cytokines Cell Mol Ther 1998;4:229-41.
4. Imhof M, Popal H, Lee JH, Zeuzem S, Milbradt R. Prevalence of hepatitis C virus antibodies and evaluation of hepatitis C virus geno types in patients with lichen planus. Dermatology 1997;195:1-5.
5. Dalekos GN, Christodoulou D, Kistis KG, Zervou EK, Hatzis J, Tsianos EV. A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 1998;10:933-9.
6. Boyd AS, Nanney LB, King LE. Immunoperoxidase evaluation of lichen planus biopsies for hepatitis C virus. Int J Dermatol 1998;37:260-2.
7. Main J, McCarron B, Thomas HC. Treatment of chronic viral hepatitis. Antivir Chem Chemother 1998;9:449-60.
8. Cacciarelli TW, Marinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996;24:6-9.
9. Martin J, Navas S, Quiroga JA, Pardo M, Carreno V. Effects of the riavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998;10:635-44.
10. Hultgren C, Milich DR, Weiland O, Salberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998;79:2381-91.
11. Davis GL, Esteban-Mur R, Rustagi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
12. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: hepatitis international therapy group. N Engl J Med 1998;339:1485-92.
13. Barbaro G, DiLorenzo G, Soldini M, Giancaspro G, Bellomo G, Belleoni G, et al. Interferon-alpha-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, control, clinical study. Am J Gastroenterol 1998;93:2445-51.
14. Kobayashi M, Chayama K, Arase Y, Tsuboia A, Saitoh S, Suzuki Y, et al. Predictive value of different hepatitis C serological assays in the treatment of chronic heptitis C with interferon α. Gastroenterology 1999;34:94-9.
15. Brouwer JT, Hansen BE, Niesters HGM, Schalm SW. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999;30:192-8.
16. Kikuchi I, Ueda A, Mihara K, Miyanaga O, Machidori H, Ishikawa E, et al. The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1998;10:859-63.
17. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998;19:568-74.
18. Hadziyannis SJ. Skin disease associated with hepatitis C virus infection. J Eur Acad Dermatol Venereol 1998;10:12-21.
19. Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994;19:841-8.
20. Daoud MS, Gibson LE, Daoud S, El-Azhary RA. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc 1995;70:559-64.
21. Marcellin P, Benhamou J-P. Autoimmune disorders associated with hepatitis C. In: Boyer JL, Ockner RK, eds. Progress in liver diseases, Vol XIII. Philadelphia: WB Saunders; 1995. p. 247-67.
22. Hadziyannis SL. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepat 1997;4:9-28.
23. Zimmermann R, Konig V, Bauditz J, Hopf U. Interferon alfa chronic hepatitis C. Lancet 1993;128:359-60.
24. Ferri C, Zignego AL, Longombardo G, Monti M, La Civita L, Lombardini F, et al. Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia. Infection 1993;21:93-7.
25. Marcellin P, Descamps V, Marinot-Peigoux M, Larzul D, Xu L, Boyer N, et al. Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. Gastroenterology 1993;104:272-7.
26. Zenda T, Okamoto R, Sanada H. A possible pathogenic relation between hepatitis C virus and essential cryoglobulinemia, rheumatoid factor and consumption of complement following interferon-beta therapy for chronic active hepatitis C Acta Hepatol Jpn 1995;36:381-5.
27. Kondo M, Horie V, Okano J, Kitamura A, Maeda N, Kawasaki H, et al. Porphyria cutanea tarda and HCV infection. Intern Hepatol Common 1995;3(Suppl):S45.
28. Doutre MS, Beylot C, Couzigou P, Long P, Royer P, Beylor J. Lichen planus and virus C hepatitis: disappearance of lichen planus under interferon alfa therapy. Dermatology 1992;184:229.
29. Strumia R, Venturini D, Boccia S, Gamberini S, Gullini S. UVA and interferon alfa therapy in a patient with lichen planus and chronic heptititis C. Int J Dermatol 1993;32:386.
30. Boccia S, Gamberini S, Dalla Libera M, Strumia R, Venturini D. Lichen planus and interferon therapy for hepatitis C. Gastroenterology 1993;105:1921-2.
31. Protzer U, Ochendorf FR, Leopolder-Ochendorf A, Holtermuller K. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993;104:903-5.
32. Barrcca T, Corsini G, Franceschini R, Gambini C, Garbaldi A, Polandi E. Lichen planus induced by interferon alpha 2a therapy for chronic active hepatitis C. Eur J Gastroenterol 1995;7:367-8.
33. Shrestha R, McKinley C, Bilir BM, Everson GT. Possible idiopathic thrombocytopenic purpura associated with natural alpha interferon therapy for chronic hepatitis C infection. Am J Gastroenterol 1995;90:1146-7.
34. Dourakis S, Deutsch M, Hadziyannis S. Immune thrombocytopenia and alpha-interferon therapy. J Hepatol 1996;25:972-5.
35. Durand JM, Cretel E, Retornaz F, Lefevre P, Kaplanski G, Soubeyrand J. Alpha interferon therapy in thrombocytopenia associated with hepatitis C virus infection. J Hepatol 1994;21:277-8.
36. Fattovich G, Giustina G, Favarato S, Ruol A. Investigators of the Italian association for the study of the liver: a survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.